ClinicalTrials.gg
Active, not recruitingNCT06571383Updated Jun 2, 2026

STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss

A Phase 4 interventional study of Semaglutide in Obesity, sponsored by Novo Nordisk A/S. Active, not recruiting at 93 sites in 13 countries. Open to participants aged 12 Years to 15 Years. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
500
Allocation
Not applicable
Ages
12 Years to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 143 studies testing semaglutide in Obesity — 68 open to participants now, 77 under way, 14 of them phase 3. Semaglutide · Obesity.

Planned enrollment
15th of 143
500 · median 100
Started
2024
with 18 others
Phase 4
40 of 143
20 open now
Primary completion
2028-11
later than 64 of 76 live
Registered
85th of 143
by date
Lead sponsor
41 of 143
Novo Nordisk A/S

Among the 143 studies testing semaglutide in Obesity, this one is the 15th largest by planned enrollment, is one of 19 that started in 2024, is one of 40 in phase 4, reaches primary completion later than 64 of the 76 other live ones, and was the 85th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

68 of the 143 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

63 more — sign in →

By country, each count listing its studies:

All 68 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 12 Years to 15 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies testing semaglutide in Obesity, or all of them as a file.
02

Study summary

The study is testing how well semaglutide can help adolescents with excess body weight to lose weight and to maintain weight loss. All participants in the study will receive semaglutide as a weekly injection. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. All participants will get semaglutide treatment for a minimum of 3 years.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
12 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study:

    1. The parent(s) or legally acceptable representative (LAR) of the participant must sign and date the Informed Consent Form, according to local requirements
    2. The participant must sign and date the Child Assent Form or provide oral assent, according to local requirements
  • Age 12 to less than 15 years at the time of signing the informed consent
  • greater than or equal to 95th percentile at screening
  • Body weight greater than 60 kg at screening

Exclusion criteria

Exclusion criteria:

  • Prepubertal status (Tanner stage 1)
  • Treatment with any medication prescribed for the indication of obesity or weight management within 90 days before screening
  • Previous or planned (during the study period) obesity treatment with surgery or a weight loss device. However, the following are allowed:

    1. Liposuction and/or abdominoplasty, if performed more than 1 year prior to screening
    2. Adjustable gastric banding, if the band has been removed more than 1 year prior to screening
    3. Intragastric balloon, if the balloon has been removed more than 1 year prior to screening
    4. Duodenal-jejunal bypass liner (e.g., Endobarrier), if the sleeve has been removed more than 1 year prior to screening
  • Endocrine, hypothalamic, or syndromic obesity
  • History of type 1 or type 2 diabetes mellitus
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Semaglutide

    2.4mg or maximum tolerated dose(MTD) injected subcutaneously (under the skin, s.c) once weekly

    Drug: Semaglutide

Interventions

  • Participants will receive semaglutide s.c(under the skin) once weekly.

06

What researchers measure

Primary outcomes

  1. Maintenance of Body Mass Index (BMI) below obesity threshold

    Measures as count of participants

    Time frame: From 1.5 years to 3 years

Secondary outcomes

  1. Maintenance of improved Body Mass Index (BMI) category

    Measured as count of participants

    Time frame: From 1.5 years to 3 years and end of continued treatment phase (up to 6 years)

  2. Tapering to zero dose

    Measured as count of participants

    Time frame: From 1.5 years to 3 years

  3. Time/dose steps before ending dose tapering

    Measured in weeks, count of dose steps

    Time frame: From 1.5 years to 3 years

  4. Achieving Body Mass Index (BMI) below obesity threshold

    Measured as count of participants

    Time frame: From baseline (day 0) to 1.5, 3 years and end of continued treatment phase (up to 6 years)

  5. Achieving any improvement in Body Mass Index (BMI) category

    Measured as count of participants

    Time frame: From baseline (day 0) to 1.5, 3 years, and end of continued treatment phase (up to 6 years)

  6. Change in Body Mass Index (BMI)

    Measured in percentage (%)

    Time frame: From baseline (day 0) to 1.5 and 3 years

  7. Body Mass Index (BMI) percentage of the 95th percentile

    Measured in percentage (%)

    Time frame: From baseline (day 0) to 1.5 and 3 years

  8. Change in Body Mass Index Standard Deviation Score (BMI SDS)

    Unitless

    Time frame: From baseline (day 0) to 1.5 and 3 years

  9. Change in waist-to-height ratio (waist [cm]/ height [cm])

    Unitless

    Time frame: From baseline (day 0) to 1.5 and 3 years

  10. Change in waist circumference

    Measured in centimeters (cm)

    Time frame: From baseline (day 0) to 1.5 and 3 years

  11. Change in HbA1c

    Measured in percentage (%) points

    Time frame: From baseline (day 0) to 1.5, 3 years and end of continued treatment phase (up to 6 years)

  12. Change in fasting plasma glucose

    Measured in millimol per liter (mmol/L), milligram per deciliter (mg/dL)

    Time frame: From baseline (day 0) to 1.5, 3 years and end of continued treatment phase (up to 6 years)

  13. Change in fasting insulin and Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)

    Measured in percentage (%)

    Time frame: From baseline (day 0) to 1.5, 3 years and end of continued treatment phase (up to 6 years)

  14. Change in high sensitivity C-reactive protein (hsCRP)

    Measured in percentage (%)

    Time frame: From baseline (day 0) to 1.5, 3 years and end of continued treatment phase (up to 6 years)

  15. Change in alanine aminotransferase (ALT), total cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), very low-density lipoprotein (VLDL) and triglycerides

    Measured in percentage (%)

    Time frame: From baseline (day 0) to 1.5, 3 years and end of continued treatment phase (up to 6 years)

  16. Change in systolic and diastolic blood pressure

    Measured in millimetres of mercury (mmHg)

    Time frame: From baseline (day 0) to 1.5, 3 years and end of continued treatment phase (up to 6 years)

  17. Change in fat mass, by dual X-ray absorptiometry (DXA) relative to total body mass

    Measured in percentage (%) points

    Time frame: From baseline (day 0) to 1.5 and 3 years

  18. Change in lean body mass, by dual X-ray absorptiometry (DXA) relative to total body mass

    Measured in percentage (%) points

    Time frame: From baseline (day 0) to 1.5 and 3 years

  19. Relative change in visceral fat mass, by dual X-ray absorptiometry (DXA)

    Measured in percentage (%)

    Time frame: From baseline (day 0) to 1.5 and 3 years

  20. Serious Adverse Event (SAE)

    Count

    Time frame: From baseline (day 0) to 1.5 years, from 1.5 to 3 years, and from 3 years to end of continued treatment phase (up to 6 years)

07

Study locations

93 sites
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Nov 2028, 49 months after the start.

Of 210 phase 4 interventional studies under Obesity, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 49 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2024
First posted
Aug 26, 2024
StartActual
Sep 17, 2024
Primary completionEst.
Nov 15, 2028
CompletionEst.
Nov 15, 2031
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06571383
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Aug 26, 2024
Start date
Sep 17, 2024
Primary completion
Nov 15, 2028 (estimated)
Completion
Nov 15, 2031 (estimated)
Last update
Jun 2, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion